Cytokine release syndrome, also termed “cytokine storm,” is the leading cause of morbidity and mortality among patients with various conditions such as sepsis. While cytokine storm is associated with multiple organ damage, acute cardiac and renal injury represents a hallmark of cytokine storm. Since recent reports have suggested that cannabidiol (CBD) may assist in the treatment of inflammatory diseases, our objective was to examine the effect of CBD on cytokine storm-induced cardiac and renal injury using the lipopolysaccharide (LPS)-induced sepsis mouse model.
Materials and Methods:
At 8 weeks of age, mice were randomly assigned to receive CBD (15 mg/kg) or vehicle one hour before a single injection of either phosphate-buffered saline or LPS (10 mg/kg) for an additional 24 h.
Results:
Our results show that CBD improves cardiac function and reduces renal injury in a mouse model of cytokine storm. Moreover, our data indicate that CBD significantly reduces systemic and renal inflammation to contribute to the improvements observed in a cytokine storm-model of cardiac and renal injury.
Conclusions:
Overall, the findings of this study suggest that CBD could be repurposed to reduce morbidity in patients with cytokine storm particularly in severe infections such as sepsis.
Get full access to this article
View all access options for this article.
References
1.
RoncoC, ReisT. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol, 2020; 16:308–310.
2.
RangaswamiJ, BhallaV, BlairJEA, et al.Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation, 2019; 139:e840–e878.
3.
UchinoS, KellumJA, BellomoR, et al.Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA, 2005; 294:813–818.
4.
MartinCM, PriestapF, FisherH, et al.A prospective, observational registry of patients with severe sepsis: The Canadian Sepsis Treatment and Response Registry. Crit Care Med, 2009; 37:81–88.
5.
SusantitaphongP, CruzDN, CerdaJ, et al.World incidence of AKI: A meta-analysis. Clin J Am Soc Nephrol, 2013; 8:1482–1493.
6.
ChengY, LuoR, WangK, et al.Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int, 2020; 97:829–838.
7.
WangD, HuB, HuC, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020; 323:1061–1069.
8.
WaikarSS, LiuKD, ChertowGM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol, 2008; 3:844–861.
9.
BagshawSM, UchinoS, BellomoR, et al.Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. Clin J Am Soc Nephrol, 2007; 2:431–439.
10.
MaayahZH, TakaharaS, FerdaoussiM, et al.The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. Biochim Biophys Acta Mol Basis Dis, 2020; 1866:165771.
11.
PengJ, FanM, AnC, et al.A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol, 2022; 130:439–456.
12.
ChenJW, BorgeltLM, BlackmerAB. Epidiolex (cannabidiol): A new hope for patients with Dravet or Lennox-Gastaut syndromes. Ann Pharmacother, 2019; 53:603–611.
13.
UritsI, BorchartM, HasegawaM, et al.An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther, 2019; 8:41–51.
14.
MaayahZH, TakaharaS, FerdaoussiM, et al.The anti-inflammatory and analgesic effects of formulated full-spectrum cannabis extract in the treatment of neuropathic pain associated with multiple sclerosis. Inflamm Res, 2020; 69:549–558.
15.
FouadAA, AlbualiWH, Al-MulhimAS, et al.Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol, 2013; 36:347–357.
16.
StanleyCP, HindWH, O'SullivanSE. Is the cardiovascular system a therapeutic target for cannabidiol?. Br J Clin Pharmacol, 2013; 75:313–322.
17.
RajeshM, MukhopadhyayP, BatkaiS, et al.Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol, 2010; 56:2115–2125.
18.
CharytoniukT, SztolsztenerK, BielawiecP, et al.Cannabidiol downregulates myocardial de novo ceramide synthesis pathway in a rat model of high-fat diet-induced obesity. Int J Mol Sci, 2022; 23.
19.
AtalayS, Jarocka-KarpowiczI, SkrzydlewskaE. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel), 2019; 9.
20.
NagarkattiP, PandeyR, RiederSA, et al.Cannabinoids as novel anti-inflammatory drugs. Future Med Chem, 2009; 1:1333–1349.
21.
NairAB, JacobS. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm, 2016; 7:27–31.
22.
ReignerBG, BleschKS. Estimating the starting dose for entry into humans: Principles and practice. Eur J Clin Pharmacol, 2002; 57:835–845.
23.
DeianaS, WatanabeA, YamasakiY, et al.Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl), 2012; 219:859–873.
24.
OhlssonA, LindgrenJE, AnderssonS, et al.Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom, 1986; 13:77–83.
25.
McCartneyD, BensonMJ, DesbrowB, et al.Cannabidiol and sports performance: A narrative review of relevant evidence and recommendations for future research. Sports Med Open, 2020; 6:27.
26.
MaayahZH, AlamAS, TakaharaS, et al.Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice. FEBS Lett, 2021; 595:1681–1695.
27.
TakaharaS, FerdaoussiM, SrnicN, et al.Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation. Am J Physiol Heart Circ Physiol, 2021; 320:H432–H446.
28.
MaayahZH, LevasseurJ, Siva PiragasamR, et al.2-Methoxyestradiol protects against pressure overload-induced left ventricular hypertrophy. Sci Rep, 2018; 8:2780.
29.
MaayahZH, AbdelhamidG, El-KadiAO. Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-kappaB. Cell Biol Toxicol, 2015; 31:241–259.
30.
MaayahZH, FerdaoussiM, TakaharaS, et al.Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology, 2021; 29:269–279.
31.
MatsumuraN, ZordokyBN, RobertsonIM, et al.Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes. Cardiovasc Res, 2018; 114:1350–1359.
32.
DurstR, DanenbergH, GallilyR, et al.Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol, 2007; 293:H3602–H3607.
33.
DoiK, LeelahavanichkulA, YuenPS, et al.Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest, 2009; 119:2868–2878.
34.
FajgenbaumDC, JuneCH. Cytokine storm. N Engl J Med, 2020; 383:2255–2273.
MartinL, DerwallM, Al ZoubiS, et al.The septic heart: Current understanding of molecular mechanisms and clinical implications. Chest, 2019; 155:427–437.
37.
MerxMW, WeberC. Sepsis and the heart. Circulation, 2007; 116:793–802.
38.
WardPA, FattahiF. New strategies for treatment of infectious sepsis. J Leukoc Biol, 2019; 106:187–192.
39.
PrescottHC, CostaDK. Improving long-term outcomes after sepsis. Crit Care Clin, 2018; 34:175–188.
40.
DamasP, LedouxD, NysM, et al.Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg, 1992; 215:356–362.
41.
UsachI, MartinezR, FestiniT, et al.Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site. Adv Ther, 2019; 36:2986–2996.
42.
GastonTE, FriedmanD. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav, 2017; 70:313–318.
43.
ElliottJ, McCoyB, CliffordT, et al.Economic evaluation of cannabinoid oil for Dravet syndrome: A cost-utility analysis. Pharmacoeconomics, 2020; 38:971–980.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
